{"id":"https://openalex.org/W3136020175","doi":"https://doi.org/10.1136/ejhpharm-2021-eahpconf.166","title":"4CPS-334 Influence of anthropometric, demographic and therapeutic factors on serum concentrations of anti-TNF drugs","display_name":"4CPS-334 Influence of anthropometric, demographic and therapeutic factors on serum concentrations of anti-TNF drugs","alternate_titles":[],"publication_year":2021,"publication_date":"2021-03-01","ids":{"openalex":"https://openalex.org/W3136020175","doi":"https://doi.org/10.1136/ejhpharm-2021-eahpconf.166","mag":"3136020175"},"language":"en","primary_location":{"id":"doi:10.1136/ejhpharm-2021-eahpconf.166","doi":"https://doi.org/10.1136/ejhpharm-2021-eahpconf.166","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ejhpharm-2021-eahpconf.166","pdf_url":"https://ejhp.bmj.com/content/ejhpharm/28/Suppl_1/A81.2.full.pdf","source":{"id":"https://openalex.org/S3012707348","display_name":"European Journal of Hospital Pharmacy","issn_l":"2047-9956","issn":["2047-9956","2047-9964"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Section 4: Clinical pharmacy services","raw_type":"proceedings-article"},"parent_works":[],"lineage":["https://openalex.org/W3136020175"],"child_works_count":0,"type":"conference-paper","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ejhp.bmj.com/content/ejhpharm/28/Suppl_1/A81.2.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"S Gimenez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126200","display_name":"Hospital Universitario Doctor Peset","ror":"https://ror.org/03971n288","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210126200"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"S Gimenez","raw_affiliation_strings":["Doctor Peset Hospital, Pharmacy, Valencia, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Doctor Peset Hospital, Pharmacy, Valencia, Spain","institution_ids":["https://openalex.org/I4210126200"]}]},{"author_position":"middle","author":{"id":null,"display_name":"J Polo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126200","display_name":"Hospital Universitario Doctor Peset","ror":"https://ror.org/03971n288","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210126200"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"J Polo","raw_affiliation_strings":["Doctor Peset Hospital, Pharmacy, Valencia, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Doctor Peset Hospital, Pharmacy, Valencia, Spain","institution_ids":["https://openalex.org/I4210126200"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111845704","display_name":"A Sendra Garc\u00eda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126200","display_name":"Hospital Universitario Doctor Peset","ror":"https://ror.org/03971n288","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210126200"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"A Sendra","raw_affiliation_strings":["Doctor Peset Hospital, Pharmacy, Valencia, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Doctor Peset Hospital, Pharmacy, Valencia, Spain","institution_ids":["https://openalex.org/I4210126200"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040010563","display_name":"Pilar Llopis","orcid":"https://orcid.org/0000-0002-4954-934X","observed_orcids":["https://orcid.org/0000-0002-4954-934X"]},"institutions":[{"id":"https://openalex.org/I4210126200","display_name":"Hospital Universitario Doctor Peset","ror":"https://ror.org/03971n288","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210126200"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"P Llopis","raw_affiliation_strings":["Doctor Peset Hospital, Pharmacy, Valencia, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Doctor Peset Hospital, Pharmacy, Valencia, Spain","institution_ids":["https://openalex.org/I4210126200"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5064290887","display_name":"M\u00f3nica Climente","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126200","display_name":"Hospital Universitario Doctor Peset","ror":"https://ror.org/03971n288","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210126200"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"M Climente","raw_affiliation_strings":["Doctor Peset Hospital, Pharmacy, Valencia, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Doctor Peset Hospital, Pharmacy, Valencia, Spain","institution_ids":["https://openalex.org/I4210126200"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210126200"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A81.2","last_page":"A82"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.004699999932199717,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-tnf-drugs","display_name":"anti-TNF drugs","score":0.7250000238418579},{"id":"https://openalex.org/keywords/infliximab","display_name":"infliximab","score":0.9660000205039978},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":1.0},{"id":"https://openalex.org/keywords/therapeutic-drug-monitoring","display_name":"therapeutic drug monitoring","score":0.8659999966621399},{"id":"https://openalex.org/keywords/serum-drug-levels","display_name":"serum drug concentration","score":0.7360000014305115},{"id":"https://openalex.org/keywords/inflammatory-bowel-disease","display_name":"inflammatory bowel disease","score":0.781000018119812},{"id":"https://openalex.org/keywords/crohn-s-disease","display_name":"Crohn's disease","score":0.8769999742507935},{"id":"https://openalex.org/keywords/ulcerative-colitis","display_name":"ulcerative colitis","score":1.0},{"id":"https://openalex.org/keywords/c-reactive-protein","display_name":"C-reactive protein","score":0.9570000171661377},{"id":"https://openalex.org/keywords/body-mass-index","display_name":"body mass index","score":0.8650000095367432},{"id":"https://openalex.org/keywords/dose-intensification","display_name":"dose intensification","score":0.6949999928474426},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.9710000157356262},{"id":"https://openalex.org/keywords/immunomodulatory-therapy","display_name":"immunomodulatory therapy","score":0.8100000023841858},{"id":"https://openalex.org/keywords/treatment-lines","display_name":"treatment lines","score":0.6240000128746033},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.32100000977516174},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.4189999997615814}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7944536209106445},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.7574132680892944},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.7159378528594971},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6545812487602234},{"id":"https://openalex.org/C2780272996","wikidata":"https://www.wikidata.org/wiki/Q1261151","display_name":"Therapeutic drug monitoring","level":3,"score":0.6138866543769836},{"id":"https://openalex.org/C2780221984","wikidata":"https://www.wikidata.org/wiki/Q131191","display_name":"Body mass index","level":2,"score":0.5875740647315979},{"id":"https://openalex.org/C151956035","wikidata":"https://www.wikidata.org/wiki/Q1132755","display_name":"Logistic regression","level":2,"score":0.5453722476959229},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5066652894020081},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.4776412546634674},{"id":"https://openalex.org/C2983394010","wikidata":"https://www.wikidata.org/wiki/Q19885330","display_name":"Continuous variable","level":2,"score":0.44629958271980286},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.43439194560050964},{"id":"https://openalex.org/C61427482","wikidata":"https://www.wikidata.org/wiki/Q6656244","display_name":"Anthropometry","level":2,"score":0.42288002371788025},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4046441316604614},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.3201170563697815},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3069306015968323},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.25157874822616577}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/ejhpharm-2021-eahpconf.166","doi":"https://doi.org/10.1136/ejhpharm-2021-eahpconf.166","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ejhpharm-2021-eahpconf.166","pdf_url":"https://ejhp.bmj.com/content/ejhpharm/28/Suppl_1/A81.2.full.pdf","source":{"id":"https://openalex.org/S3012707348","display_name":"European Journal of Hospital Pharmacy","issn_l":"2047-9956","issn":["2047-9956","2047-9964"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Section 4: Clinical pharmacy services","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/ejhpharm-2021-eahpconf.166","doi":"https://doi.org/10.1136/ejhpharm-2021-eahpconf.166","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ejhpharm-2021-eahpconf.166","pdf_url":"https://ejhp.bmj.com/content/ejhpharm/28/Suppl_1/A81.2.full.pdf","source":{"id":"https://openalex.org/S3012707348","display_name":"European Journal of Hospital Pharmacy","issn_l":"2047-9956","issn":["2047-9956","2047-9964"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Section 4: Clinical pharmacy services","raw_type":"proceedings-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3136020175.pdf","grobid_xml":"https://content.openalex.org/works/W3136020175.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7138897017","https://openalex.org/W3010864452","https://openalex.org/W2999623751","https://openalex.org/W7211893482","https://openalex.org/W2942517774","https://openalex.org/W4407254582","https://openalex.org/W2790133975","https://openalex.org/W2188248721","https://openalex.org/W4391165439","https://openalex.org/W4393005718"],"abstract_inverted_index":{"Background":[0],"and":[1,39,45,56,75,87,122,146,152,164,193,263,319,330,350,356],"importance":[2],"Therapeutic":[3],"drug":[4,32,206,334],"monitoring":[5],"is":[6,34],"known":[7],"to":[8,200,225,245,282,297,306,316,326],"optimise":[9],"clinical":[10,109],"results":[11],"in":[12],"inflammatory":[13,345],"bowel":[14],"disease":[15,341],"(IBD)":[16],"patients":[17,71,247],"receiving":[18],"anti-tumour":[19],"necrosis":[20],"factor":[21],"(TNF)":[22],"drugs.":[23,54],"The":[24],"influence":[25,49,228],"of":[26,52,229,339,354,363,374,393,397],"several":[27],"patient":[28],"factors":[29],"on":[30,184,232],"these":[31],"levels":[33,353],"not":[35],"well":[36],"established.":[37],"Aim":[38],"objectives":[40],"To":[41],"identify":[42,201],"anthropometric,":[43],"demographic":[44,106],"therapeutic":[46,123,159,333,366,377],"variables":[47,99,124,155,173,188,202,231],"that":[48,203],"serum":[50,81],"concentrations":[51,90,335],"anti-TNF":[53,157],"Material":[55],"methods":[57],"A":[58,195],"retrospective,":[59],"observational,":[60],"descriptive":[61],"study":[62],"was":[63,198,223,256,266],"conducted":[64],"at":[65],"a":[66],"tertiary":[67],"hospital":[68],"(2016\u20132019).":[69],"IBD":[70],"with":[72,275,290],"infliximab":[73],"(IFX)":[74],"adalimumab":[76],"(ADA)":[77],"trough":[78],"steady":[79],"state":[80],"concentration":[82],"(Cs)":[83],"were":[84,91,156,174,189,238,261,272,287],"included.":[85],"Drug":[86],"anti-drug":[88,142],"antibody":[89],"quantified":[92],"using":[93,208],"the":[94,185,216,227,337,361,372],"ELISA":[95],"assay":[96],"(Promonitor).":[97],"Explanatory":[98],"were:":[100],"anthropometric":[101],"(body":[102],"mass":[103],"index":[104],"(BMI)),":[105],"(age,":[107],"sex),":[108],"(albumin,":[110],"haemoglobin,":[111],"leucocytes,":[112],"C":[113],"reactive":[114],"protein":[115],"(CRP)":[116],"<5":[117],"mg/L":[118],"or":[119,133,139,180,215],">5":[120],"mg/L)":[121],"(dose":[125],"intensity:":[126],"intensified":[127,357],"(>5":[128],"mg/kg/8":[129],"weeks":[130],"for":[131,137,348,386],"IFX":[132,165,270],">40":[134],"mg":[135],"biweekly":[136],"ADA)":[138],"non-":[140],"intensified;":[141],"antibodies;":[143],"immunomodulatory":[144],"treatment;":[145],"treatment":[147],"line":[148],"(first":[149],"vs":[150],"second":[151],"beyond).":[153],"Outcome":[154],"Cs,":[158],"ADA":[160,285,349,358,365,376,380],"Cs":[161,166,236,271,286],"\u22658":[162],"\u00b5g/mL":[163],"\u22653.5":[167],"\u00b5g/l.":[168],"For":[169],"statistical":[170],"analysis,":[171],"continuous":[172],"expressed":[175,190],"as":[176,191],"mean":[177,254],"(95%":[178,279,294,303,313,323],"CI)":[179],"median":[181,264],"(IQR),":[182],"depending":[183],"distribution;":[186],"categorical":[187],"number":[192],"frequency.":[194],"univariate":[196],"analysis":[197],"performed":[199,224],"may":[204,383],"affect":[205],"concentrations,":[207],"independent":[209],"samples":[210],"t":[211],"tests":[212],"(continuous":[213],"variables)":[214],"\u03c72":[217],"test":[218],"(categorical":[219],"variables).":[220],"Logistic":[221],"regression":[222],"quantify":[226],"explanatory":[230],"Cs.":[233],"Results":[234],"640":[235],"determinations":[237],"included":[239],"(372":[240],"ADA,":[241],"247":[242],"IFX)":[243],"corresponding":[244],"185":[246],"(47":[248],"ulcerative":[249],"colitis,":[250],"138":[251],"Crohn\u2019s":[252],"disease):":[253],"age":[255],"41":[257],"(12)":[258],"years,":[259],"50%":[260],"women":[262],"BMI":[265,320,370],"24":[267],"(5)":[268],"kg/m2.":[269],"significantly":[273,288],"associated":[274,289],"CRP":[276,291,344],"(OR":[277,292,301,311,321],"4.68":[278],"CI":[280,295,304,314,324],"2.49":[281],"8.81);":[283],"p<0.001).":[284],"4.58":[293],"2.45":[296],"8.56);":[298],"p<0.001),":[299],"albumin":[300,355],"2.175":[302],"1.06":[305],"4.46);":[307],"p=0.034),":[308],"dose":[309,359],"intensity":[310],"3.11":[312],"1.58":[315],"6.12);":[317],"p=0.001)":[318],"0.88":[322],"0.82":[325],"0.95);":[327],"p=0.001).":[328],"Conclusion":[329],"relevance":[331],"Achieving":[332],"increase":[336],"probability":[338,362,373],"obtaining":[340],"control":[342],"(low":[343],"marker)":[346],"both":[347],"IFX.":[351],"High":[352],"increased":[360],"achieving":[364,375],"levels,":[367],"while":[368],"high":[369],"decreased":[371],"levels.":[378],"Stablished":[379],"fixed":[381],"dosing":[382],"be":[384],"reconsidered":[385],"tailored":[387],"dosing.":[388],"References":[389],"and/or":[390],"acknowledgements":[391],"Conflict":[392],"interest":[394,398],"No":[395],"conflict":[396]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3136020175","counts_by_year":[],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2021-03-29T00:00:00"}
